IL6 and breast cancer: In in vitro study, oroxylin A inhibited cell proliferation, EMT, migration, and invasion through suppressed inflammatory factors (TNF-α, IL-6, and IL-8) and suppressed the NF-κB signaling pathway in MDA-MB-231 BC cells [161].